Zepbound and Wegovy are prescription drugs used for weight loss and weight management. Compare their uses, cost, effectiveness, side effects, and more.

About 200,000 CVS members on Zepbound have been affected, analysts say. U.S. total prescription volume for Zepbound in the week ended July 18 dropped 4% from the week before, while Wegovy ...

Patients taking the GLP-1 weight loss drug Zepbound face mandatory switch to Wegovy after CVS Caremark removed the Eli Lilly medication from its preferred coverage list, citing rising costs.

The 50-year-old is now on Novo Nordisk ’s Wegovy, but worries because it is less effective. Studies have shown Wegovy helps people lose less weight, on average, than Zepbound.

As of July 1, CVS Caremark — one of the biggest pharmacy benefit managers in the U.S. — dropped Zepbound (tirzepatide) from its preferred drug list, replacing it with Wegovy (semaglutide).

Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

Drugs like Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) are delivering phenomenal results in a country where some 75% of adults are overweight or obese.

Both Novo Nordisk, the maker of Wegovy, and Eli Lilly, the maker of Zepbound, say there will continue to be shortages but they plan to continue to increase overall supply.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those with previous adverse reactions.